Fangzhou and Tencent Healthcare Unveil Comprehensive AI Solution for Chronic Disease Management
SHANGHAI, Nov. 27, 2025 — Fangzhou Inc. (referred to as “Fangzhou” or the “Company”) (HKEX: 06086), a prominent provider of AI-powered Internet healthcare solutions, has collaborated with Tencent Healthcare to unveil a comprehensive “AI+Chronic Disease Management” solution. This initiative signifies a significant advancement in integrating artificial intelligence more broadly into China’s healthcare industry. Through this collaboration, industry collaborators will gain access to an end-to-end technological framework covering model development, real-world validation, and implementation, designed to propel chronic disease management towards more intelligent and highly efficient service provision.
This solution leverages Fangzhou’s AI+H2H (Hospital to Home) ecosystem, a foundational architecture that integrates proprietary large-model functionalities directly into chronic disease management processes. Tencent Cloud, a premier cloud services provider, contributes substantial expertise in critical technological areas such as cloud computing, big data, and artificial intelligence. This strategic alliance is set to establish a solid technological groundwork for the evolution of AI-augmented chronic disease management.
Fangzhou Inc. and Tencent Healthcare have collaboratively unveiled an extensive “AI+Chronic Disease Management” solution
Dr. Xie Fangmin, the Founder, Chairman, and CEO of Fangzhou, stated: “Through the integration of Fangzhou’s specialized knowledge in healthcare and chronic disease management with Tencent Healthcare’s robust industrial infrastructure, we are delivering proven, scalable AI capabilities throughout the broader healthcare ecosystem, thereby establishing an elevated benchmark for the progression of chronic disease management within China.”
This unveiling comes on the heels of Fangzhou’s recent expansion in AI initiatives. The “medical report interpretation” feature, introduced by the Company in October, garnered significant uptake, effectively meeting a common patient demand for clearer understanding of intricate laboratory outcomes. Increased user engagement and session frequency further underscore rising user assurance in AI’s potential.
Safety and regulatory adherence are fundamental to Fangzhou’s methodology. To mitigate the potential for AI inaccuracies or “hallucinations” within critical clinical environments, the company has deployed several protective measures. These include reinforcement learning leveraging carefully assembled knowledge bases, rule-driven oversight, and verification checks for alignment with specific medical scenarios.
Fangzhou developed its model utilizing Tencent Healthcare’s TI platform, taking advantage of integrated training, evaluation, and deployment processes to facilitate ongoing model refinement. Tencent Healthcare’s vector database, which can house hundreds of billions of specialized medical knowledge items, delivers semantic retrieval in milliseconds, thereby enhancing the precision and factual accuracy of RAG-powered results. To guarantee compliance, Tencent Healthcare’s AI security Web Application Firewall (WAF) provides detailed threat identification and encrypted protection for confidential medical information, ensuring the solution adheres to regulatory requirements for AI in clinical use.
This collaboration is in strong alignment with the recent directives from the National Health Commission regarding the creation of secure and standardized “AI + healthcare” applications. Both organizations affirmed that their combined solution is poised to hasten digital transformation in chronic care, bolster the provision of medical services, and contribute to national health objectives outlined in the “Healthy China 2030” initiative.
About Tencent Healthcare
Tencent Healthcare functions as Tencent’s dedicated healthcare service platform, utilizing the WeChat ecosystem and artificial intelligence technologies to construct a unified service framework.
About Fangzhou Inc.
Fangzhou Inc. (HKEX: 06086) stands as China’s foremost online platform for chronic disease management, serving 52.8 million registered users and 229,000 medical professionals as of June 30, 2025. The Company focuses on providing customized medical treatment and AI-driven precision medicine solutions. To learn more, visit .
Media Contact
For additional questions or interview requests, kindly contact:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com
Disclaimer: Forward-looking statements are included in this press release. Actual outcomes could vary significantly from projections due to numerous elements. Readers should exercise caution and not depend excessively on these statements.
An accompanying photograph for this announcement can be viewed at:
